ATE293689T1 - Ein chemokin rezeptor für mcp-i, mip-i alpha und/oder rantes.seine verwendung - Google Patents

Ein chemokin rezeptor für mcp-i, mip-i alpha und/oder rantes.seine verwendung

Info

Publication number
ATE293689T1
ATE293689T1 AT96900656T AT96900656T ATE293689T1 AT E293689 T1 ATE293689 T1 AT E293689T1 AT 96900656 T AT96900656 T AT 96900656T AT 96900656 T AT96900656 T AT 96900656T AT E293689 T1 ATE293689 T1 AT E293689T1
Authority
AT
Austria
Prior art keywords
rantes
mip
mcp
chemokine receptor
alpha
Prior art date
Application number
AT96900656T
Other languages
English (en)
Inventor
Timothy Nigel Carl Wells
Christine Anna Power
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE293689(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE293689T1 publication Critical patent/ATE293689T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
AT96900656T 1995-01-27 1996-01-24 Ein chemokin rezeptor für mcp-i, mip-i alpha und/oder rantes.seine verwendung ATE293689T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501683.8A GB9501683D0 (en) 1995-01-27 1995-01-27 Substances and their uses
PCT/GB1996/000143 WO1996023068A1 (en) 1995-01-27 1996-01-24 A chemokine receptor able to bind to mcp-1, mip-1 alpha and/or rantes. its uses

Publications (1)

Publication Number Publication Date
ATE293689T1 true ATE293689T1 (de) 2005-05-15

Family

ID=10768728

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96900656T ATE293689T1 (de) 1995-01-27 1996-01-24 Ein chemokin rezeptor für mcp-i, mip-i alpha und/oder rantes.seine verwendung

Country Status (9)

Country Link
US (4) US6150132A (de)
EP (1) EP0805859B2 (de)
JP (2) JP3771585B2 (de)
AT (1) ATE293689T1 (de)
AU (1) AU4455896A (de)
DE (1) DE69634627T3 (de)
ES (1) ES2240989T5 (de)
GB (1) GB9501683D0 (de)
WO (1) WO1996023068A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6737513B1 (en) 1996-06-07 2004-05-18 Icos Corporation Macrophage derived chemokine (MDC) and chemokine analogs and assay to identify modulators of MDC activity, and therapeutic uses for same
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US7018627B1 (en) 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
EP0883687B1 (de) * 1996-03-01 2004-10-27 Euroscreen S.A. Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
US6258527B1 (en) 1996-05-20 2001-07-10 The Aaron Diamond Aids Research Center Methods of identifying g-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
US5939320A (en) * 1996-05-20 1999-08-17 New York University G-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
US6057102A (en) * 1996-08-08 2000-05-02 The Aaron Diamond Aids Research Center HIV coreceptor mutants
US5955303A (en) * 1997-03-06 1999-09-21 Incyte Pharmaceuticals, Inc. Human chemokine receptor-like protein
US6204024B1 (en) 1997-09-12 2001-03-20 Akzo Nobel N.V. CCR5 RNA transcription based amplification assay
US6121023A (en) 1998-01-22 2000-09-19 Akzo Nobel N.V. Isothermal transcription based assay for the detection and quantification of the chemokine rantes
US6287805B1 (en) 1998-03-20 2001-09-11 Millennium Pharmaceuticals, Inc. Nucleic acid molecules of the protein-coupled heptahelical receptor superfamily and uses therefor
US6420121B1 (en) * 1998-08-31 2002-07-16 Oregon Health Sciences University Prevention of cell migration initiation with CMV US28 receptor antagonists
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
US6488930B1 (en) 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
ES2156526B1 (es) * 1999-01-20 2002-02-01 Smithkline Beecham Sa Metabolitos de streptomyces cacaoi como inhibidores de la proteina quimioatrayente de monocitos 1.
EP1176195B1 (de) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Verfahren zur kontrolle der aktivität von immunologisch funktionellem molekül
JP3707303B2 (ja) * 1999-06-30 2005-10-19 株式会社日立製作所 ヒスタミン計測方法およびヒスタミン計測装置
CA2401491C (en) 2000-03-03 2011-07-05 Kyowa Kirin Co., Ltd. Ccr4-binding antibody and diagnostic and therapeutic uses thereof
AU2001288682A1 (en) 2000-08-30 2002-03-13 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2002030464A1 (en) * 2000-10-11 2002-04-18 Daiichi Pharmaceutical Co., Ltd. Novel drugs for liver diseases
KR100360410B1 (ko) * 2000-11-14 2002-11-13 삼성전자 주식회사 자기 정렬된 컨택 구조를 갖는 디램 소자와 듀얼 게이트구조의 로직 소자가 복합된 ｍｄｌ 반도체 소자의 제조 방법
EP1399184A2 (de) * 2000-12-01 2004-03-24 Schering Corporation Verwendungen von säugetiergenen und verwandten reagenzien
CA2437201C (en) * 2001-02-02 2008-11-18 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US20020165161A1 (en) * 2001-05-04 2002-11-07 Surromed, Inc. Chemokine-binding proteins for treating congestive heart failure
WO2003018549A2 (en) * 2001-08-30 2003-03-06 Chemocentryx, Inc. Bicyclic compounds as inhibitors of chemokine binding to us28
CA2458627C (en) 2001-08-31 2013-09-10 Kyowa Kirin Co., Ltd. Human cdr-grafted antibody and antibody fragment thereof
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
WO2003084569A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
AU2003260072A1 (en) 2002-08-27 2004-03-19 Bristol-Myers Squibb Company Antagonists of chemokine receptors
CA2559809A1 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Antibodies against human g-protein chemokine receptor (ccr5) hdgnr10
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5179078A (en) * 1989-05-12 1993-01-12 Dana Farber Cancer Institute Method of suppressing tumor formation in vivo
AU5293293A (en) * 1992-09-28 1994-04-26 Board Of Regents, The University Of Texas System Methods and compositions for treatment of allergic disease
DK0669979T3 (da) * 1992-11-10 2006-03-06 Genentech Inc C-C CKR-1, kemokinreceptor
US5474983A (en) * 1993-03-15 1995-12-12 The Research Foundation Of State University Of New York Method of inhibiting pro-inflammatory mediator release from basophils and mast cells
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
EP0740701B1 (de) * 1994-01-13 2006-12-06 The Regents of the University of California Monocyten protein rezeptoren aus säugern, mit chemoattraktion auslösender wirkung
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses

Also Published As

Publication number Publication date
DE69634627T2 (de) 2006-03-02
ES2240989T3 (es) 2005-10-16
JP2003038191A (ja) 2003-02-12
WO1996023068A1 (en) 1996-08-01
JPH10513046A (ja) 1998-12-15
US20020187930A1 (en) 2002-12-12
AU4455896A (en) 1996-08-14
ES2240989T5 (es) 2008-12-16
US7183063B2 (en) 2007-02-27
US20020160015A1 (en) 2002-10-31
US7655425B2 (en) 2010-02-02
EP0805859A1 (de) 1997-11-12
US6919432B2 (en) 2005-07-19
DE69634627D1 (de) 2005-05-25
JP3771585B2 (ja) 2006-04-26
DE69634627T3 (de) 2008-12-11
US20050014695A1 (en) 2005-01-20
EP0805859B2 (de) 2008-06-25
GB9501683D0 (en) 1995-03-15
EP0805859B1 (de) 2005-04-20
US6150132A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
ATE293689T1 (de) Ein chemokin rezeptor für mcp-i, mip-i alpha und/oder rantes.seine verwendung
Ling et al. Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation
Jimenez et al. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis
AU2003288675A8 (en) Antibodies against PD-1 and uses therefor
Sebastiani et al. CCL22‐induced responses are powerfully enhanced by synergy inducing chemokines via CCR4: evidence for the involvement of first β‐strand of chemokine
DE69813237D1 (de) Zusammensetzungen zur behandlung von durch ccr5 mediatierten erkrankungen
Gómez et al. Thorns as induced mechanical defense in a long‐lived shrub (Hormathophylla spinosa, Cruciferae)
DE69508093D1 (de) Substituierte piperidine für die behandlung von allergischen krankheiten
DE60219801D1 (de) KOMPLEMENT-INHIBITOREN DIE AN C5 UND C5a BINDEN OHNE DIE BILDUNG VON C5b ZU HEMMEN
DE60228073D1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
Koren‐Michowitz et al. Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC
EP0630244A4 (de) Muscarinagonisten.
ES2128544T3 (es) Pirrolopirimidinas como antagonistas del crf.
Tsai et al. Origin of osteoclasts: osteoclast precursor cells
Gouwy et al. CXCR4 and CCR5 ligands cooperate in monocyte and lymphocyte migration and in inhibition of dual‐tropic (R5/X4) HIV‐1 infection
DE60323091D1 (de) Autoimmunerkrankungen und nadph-oxidase-defekte
Luce et al. Decrease in CD38+ TH2A cell frequencies following immunotherapy with house dust mite tablet correlates with humoral responses
TNSN05158A1 (fr) Association destinee au traitement de l'adhd
Park et al. Changes of frequency and expression level of CD161 in CD8+ T cells and natural killer T cells in peripheral blood of patients with systemic lupus erythematosus
ATE284398T1 (de) N-imidazolyl-alkyl substituierte cyklische amine als histamin-h3 agonisten oder antagonisten
DE50009113D1 (de) Gegen ccr5 gerichtete antikörperkonstrukte und ihre verwendung in der behandlung von autoimmunkrankheiten
Manukyan et al. Antiphospholipid antibody-mediated NK cell cytotoxicity
ATE343398T1 (de) Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge
EP1255112A3 (de) Behandlung von T-Zellen vermittelter Krankheiten
EP1241933A4 (de) Zellen mit defizientem melanocortin-3-rezeptor, nicht-menschliche transgene tiere und verfahren zur auswahl von substanzen, die das körpergewicht regulieren können

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties